Literature DB >> 24986256

Time course study of the antigen-specific immune response to a PLGA microparticle vaccine formulation.

Qian Wang1, Melody T Tan2, Brian P Keegan1, Meagan A Barry3, Michael J Heffernan4.   

Abstract

Microparticle-based vaccine delivery systems are known to promote enhanced immune responses to protein antigens and can elicit TH1-biased responses when used in combination with Toll-like receptor (TLR) agonists. It is important to understand the kinetics of the immune responses to microparticle-based protein vaccines in order to predict the duration of protective immunity and to optimize prime-boost vaccination regimens. We carried out a 10-week time course study to investigate the magnitude and kinetics of the antibody and cellular immune responses to poly(lactic-co-glycolic acid) (PLGA) microparticles containing 40 μg ovalbumin (OVA) protein and 16 μg CpG-ODN adjuvant (MP/OVA/CpG) in comparison to OVA-containing microparticles, soluble OVA plus CpG, or OVA formulated with Alhydrogel(®) aluminum adjuvant. Mice vaccinated with MP/OVA/CpG developed the highest TH1-associated IgG2b and IgG2c antibody titers, while also eliciting TH2-associated IgG1 antibody titers on par with Alhydrogel(®)-formulated OVA, with all IgG subtype titers peaking at day 56. The MP/OVA/CpG vaccine also induced the highest antigen-specific splenocyte IFN-γ responses, with high levels of IFN-γ responses persisting until day 42. Thus the MP/OVA/CpG formulation produced a sustained and heightened humoral and cellular immune response, with an overall TH1 bias, while maintaining high levels of IgG1 antibody equivalent to that seen with Alhydrogel(®) adjuvant. The time course kinetics study provides a useful baseline for designing vaccination regimens for microparticle-based protein vaccines.
Copyright © 2014 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Drug delivery; Immunostimulation; Microsphere; Poly(lactic-co-glycolic acid) (PLGA); Vaccine

Mesh:

Substances:

Year:  2014        PMID: 24986256     DOI: 10.1016/j.biomaterials.2014.05.067

Source DB:  PubMed          Journal:  Biomaterials        ISSN: 0142-9612            Impact factor:   12.479


  12 in total

Review 1.  Peptide/protein vaccine delivery system based on PLGA particles.

Authors:  Mojgan Allahyari; Elham Mohit
Journal:  Hum Vaccin Immunother       Date:  2016-03-03       Impact factor: 3.452

2.  Tunable degradation of acetalated dextran microparticles enables controlled vaccine adjuvant and antigen delivery to modulate adaptive immune responses.

Authors:  Naihan Chen; Monica M Johnson; Michael A Collier; Matthew D Gallovic; Eric M Bachelder; Kristy M Ainslie
Journal:  J Control Release       Date:  2018-02-02       Impact factor: 9.776

3.  Investigation of tunable acetalated dextran microparticle platform to optimize M2e-based influenza vaccine efficacy.

Authors:  Naihan Chen; Matthew D Gallovic; Pamela Tiet; Jenny P-Y Ting; Kristy M Ainslie; Eric M Bachelder
Journal:  J Control Release       Date:  2018-09-24       Impact factor: 9.776

4.  A therapeutic nanoparticle vaccine against Trypanosoma cruzi in a BALB/c mouse model of Chagas disease.

Authors:  Meagan A Barry; Qian Wang; Kathryn M Jones; Michael J Heffernan; Munir H Buhaya; Coreen M Beaumier; Brian P Keegan; Bin Zhan; Eric Dumonteil; Maria Elena Bottazzi; Peter J Hotez
Journal:  Hum Vaccin Immunother       Date:  2016-02-18       Impact factor: 3.452

5.  Rationalization of a nanoparticle-based nicotine nanovaccine as an effective next-generation nicotine vaccine: A focus on hapten localization.

Authors:  Zongmin Zhao; Yun Hu; Theresa Harmon; Paul Pentel; Marion Ehrich; Chenming Zhang
Journal:  Biomaterials       Date:  2017-05-19       Impact factor: 12.479

Review 6.  PLGA Nanoparticles as an Efficient Platform in Protein Vaccines Against Toxoplasma gondii.

Authors:  Mojgan Allahyari
Journal:  Acta Parasitol       Date:  2022-01-11       Impact factor: 1.440

7.  Adjuvant-Loaded Subcellular Vesicles Derived From Disrupted Cancer Cells for Cancer Vaccination.

Authors:  Alexander S Cheung; Sandeep T Koshy; Alexander G Stafford; Maartje M C Bastings; David J Mooney
Journal:  Small       Date:  2016-03-08       Impact factor: 13.281

8.  Injectable, Ribbon-Like Microconfetti Biopolymer Platform for Vaccine Applications.

Authors:  Kathryn M Moore; Cole J Batty; Rebeca T Stiepel; Christopher J Genito; Eric M Bachelder; Kristy M Ainslie
Journal:  ACS Appl Mater Interfaces       Date:  2020-08-24       Impact factor: 9.229

9.  Expression and purification of an engineered, yeast-expressed Leishmania donovani nucleoside hydrolase with immunogenic properties.

Authors:  Elissa M Hudspeth; Qian Wang; Christopher A Seid; Molly Hammond; Junfei Wei; Zhuyun Liu; Bin Zhan; Jeroen Pollet; Michael J Heffernan; C Patrick McAtee; David A Engler; Risë K Matsunami; Ulrich Strych; Oluwatoyin A Asojo; Peter J Hotez; Maria Elena Bottazzi
Journal:  Hum Vaccin Immunother       Date:  2016-02-02       Impact factor: 3.452

10.  Drug-nanoencapsulated PLGA microspheres prepared by emulsion electrospray with controlled release behavior.

Authors:  Shenglian Yao; Huiying Liu; Shukui Yu; Yuanyuan Li; Xiumei Wang; Luning Wang
Journal:  Regen Biomater       Date:  2016-09-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.